Healthtech Series B Investors & VC Firms
1216 firms in this list, with a median first check of $750K. 285 of them lead rounds. Generated from verified public data and updated continuously.
REMUS Capital
BostonPre-Seed–Series B$25K – $20M
13 people
GSR United Capital
BeijingSeed–Late Stage$98K – $50M
DG Incubation
Pre-Seed–Growth
1 person
Necessary Ventures
San FranciscoPre-Seed–Late Stage$1M – $2M
10 people
VKAV (Verod-Kepple Africa Ventures)
LagosSeed–Growth
16 people
Ansa Capital
New YorkSeries A–Series B$5M – $15M
6 people
Planven Entrepreneur Ventures
ZurichSeed–Late Stage$10M – $20M
18 people
PLUS Capital
VeniceSeed–Late Stage$100K – $1M
11 people
Lilly Asia Ventures
Hong KongPre-Seed–Late Stage
1 person
New Alliance Capital
ShanghaiSeed–Late Stage
25 people
Spring Activator
VancouverPre-Seed–Late Stage
25 people
Third Eye Capital
TorontoSeed–Late Stage$5M – $100M
22 people
Verlinvest
BrusselsSeed–Late Stage
13 people
Sciety
StockholmSeed–Growth
21 people
Fast Track Initiative
TokyoPre-Seed–Growth$1.2M – $184M
2 people
Sawari Ventures
CairoSeed–Growth$200K – $2M
16 people
MedTech Actuator
Seed–Series B
Gresham House Ventures
LondonSeed–Late Stage$1.3M – $26M
11 people
Dimension Capital
San FranciscoSeed–Late Stage$1M – $10M
13 people
Guinness Ventures
LondonSeries A–Growth
16 people
Quan Capital
ShanghaiSeed–Late Stage
16 people
UCL Technology Fund
LondonPre-Seed–Growth$320K – $9M
13 people
Ajax Health
Menlo ParkSeed–Late Stage
23 people
Bill & Melinda Gates Foundation
SeattlePre-Seed–Growth
23 people
Related lists
Series B Investors & VC Firms (4094)Healthtech Investors & VC Firms (3208)Healthtech Seed Investors & VC Firms (2488)Healthtech Series A Investors & VC Firms (2210)Series B Investors & VC Firms in United States (1625)Healthtech Investors & VC Firms in United States (1616)Healthtech Pre-Seed Investors & VC Firms (1328)SaaS Series B Investors & VC Firms (1317)Series B Investors & VC Firms in Global (1265)Enterprise Software Series B Investors & VC Firms (1242)
Data sourced from public filings and firms' own websites — see our methodology.





























































